It was reported through a research article identifying the absorb bioresorbable vascular scaffold that was related to the following outcomes: myocardial infarction, thrombosis, ischemia and delayed endothelialization.Specific patient information is documented as unknown.Details are listed in the article, titled imaging and 2-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold: the meres-1 extend trial.
|
The devices were not returned for evaluation.A review of the lot history records and complaint histories could not be conducted because the part and lot numbers were not provided.The reported patient effects of myocardial infarction, thrombosis and ischemia, as listed in the bioresorbable vascular scaffold (bvs) system, absorb, electronic instructions for use are known adverse events associated with the use of a coronary scaffold in native coronary arteries.Based on the information reviewed, a conclusive cause for the reported difficulties and patient effects could not be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.Article attached: imaging and 2-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold: the meres-1 extend trial.
|